Category: Biosimilars

Biosimilars generally cost 15% to 45% less than the originator biologic, making it highly likely that **is Truxima cheaper than rituximab?** Yes, it is, and this article explains why these cost savings are so crucial for patients and the healthcare system. Approved in 2018 as the first rituximab biosimilar, Truxima (rituximab-abbs) was launched with a significant discount compared to the brand-name Rituxan.

The U.S. Food and Drug Administration (FDA) first approved Truxima (rituximab-abbs) in 2018 as a biosimilar to Rituxan [1.3.1]. This raises a critical question for patients and providers: Is Truxima as good as Rituxan? This article examines the evidence.

Did you know that in the U.S., biosimilars like Hulio entered the market after Humira's patents expired, offering more affordable treatment options? The core question, **Is Hulio the same as Humira?**, has a nuanced answer concerning their biological nature, safety, and effectiveness.

Despite common confusion, a recent FDA approval highlights that Cimerli and Avastin are fundamentally distinct medications. To be clear, **is Cimerli the same as Avastin?** The answer is no, as Cimerli is a biosimilar drug used for retinal diseases while Avastin is an original biologic primarily for cancer treatment.